Howard Financial Services’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$347K Buy
2,147
+27
+1% +$4.5K 0.04% 166
2026
Q2
$402K Buy
+2,120
New +$399K 0.04% 147
2026
Q1
– Sell
-2,120
Closed -$390K – 226
2025
Q4
$390K Hold
2,120
– – 0.05% 133
2025
Q3
$325K Hold
2,120
– – 0.04% 141
2025
Q2
$296K Sell
2,120
-305
-13% -$42.7K 0.04% 137
2025
Q1
$356K Hold
2,425
– – 0.05% 129
2024
Q4
$318K Buy
2,425
+305
+14% +$42.7K 0.04% 138
2024
Q3
$330K Hold
2,120
– – 0.05% 119
2024
Q2
$331K Hold
2,120
– – 0.05% 114
2024
Q1
$287K Sell
2,120
-1,997
-49% -$264K 0.05% 128
2023
Q4
$555K Hold
4,117
– – 0.11% 76
2023
Q3
$558K Buy
4,117
+28
+0.7% +$3.82K 0.13% 69
2023
Q2
$585K Hold
4,089
– – 0.14% 65
2023
Q1
$568K Buy
4,089
+58
+1% +$7.8K 0.14% 66
2022
Q4
$547K Hold
4,031
– – 0.14% 65
2022
Q3
$442K Buy
4,031
+31
+0.8% +$3.93K 0.14% 68
2022
Q2
$529K Buy
+4,000
New +$525K 0.18% 50

Other funds holding AZN

Howard Financial Services's AZN Position: Q3 2026 in Review

Howard Financial Services increased its AstraZeneca (AZN) stake by 1.3% in Q3 2026, buying an estimated $4.5K and bringing the position to 2,147 shares worth $347K. The position accounts for 0.04% of the portfolio, ranked #166.

Howard Financial Services first reported a position in AZN in Q2 2022 and has held it in 17 quarters since. The position peaked at $585K in Q2 2023. 1,444 funds tracked by Wall St. Rank hold AZN as of Q3 2026.

  • Howard Financial Services held 2,147 shares of AstraZeneca worth $347K as of Q3 2026.
  • Howard Financial Services bought 27 AstraZeneca shares in Q3 2026, an estimated $4.5K.
  • AstraZeneca made up 0.04% of Howard Financial Services's portfolio in Q3 2026, its #166 holding.
  • Howard Financial Services first reported a position in AstraZeneca in Q2 2022 and has held it in 17 quarters since.
  • Howard Financial Services's AstraZeneca position peaked at $585K in Q2 2023.
  • 1,444 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2026.

Based on Howard Financial Services's 13F filing for Q3 2026, filed 15 Oct 2026.